General Information of Drug (ID: DMP4HR2)

Drug Name
TG003 Drug Info
Synonyms Clk inhibitor; TG 003; TG-003
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
1893668
TTD Drug ID
DMP4HR2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Patented Agent(s)
Drug(s) Targeting CDC-like kinase 1 (CLK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
leucettine L41 DMBYND6 Discovery agent N.A. Investigative [4]
PMID23642479C17 DM4JWMA Discovery agent N.A. Investigative [5]
ML315 DMNOREK Discovery agent N.A. Investigative [5]
KH-CB19 DMSOB3U Discovery agent N.A. Investigative [6]
Drug(s) Targeting CDC-like kinase 2 (CLK2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID23642479C17 DM4JWMA Discovery agent N.A. Investigative [5]
ML315 DMNOREK Discovery agent N.A. Investigative [5]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Harmine DMPA5WD Discovery agent N.A. Patented [3]
PMID28766366-Compound-Scheme21Left DMWTRUK N. A. N. A. Patented [3]
PMID28766366-Compound-Scheme21Right DMF3X40 N. A. N. A. Patented [3]
PMID28766366-Compound-Scheme14BINDY DMBQ0RN N. A. N. A. Patented [3]
PMID28766366-Compound-Scheme2WO2012/098065bottom DMO4Q95 N. A. N. A. Patented [3]
PMID28766366-Compound-Scheme16DMAT DMQ5UEA N. A. N. A. Patented [3]
PMID28766366-Compound-Scheme7WO2012/098070upper DMGAQR5 N. A. N. A. Patented [3]
PMID28766366-Compound-Scheme9EHT1610 DMMZGC8 N. A. N. A. Patented [3]
PMID28766366-Compound-Scheme9EHT5372 DM0O18N N. A. N. A. Patented [3]
PMID28766366-Compound-Scheme25-2 DM7OGWH N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CDC-like kinase 1 (CLK1) TTE6YDG CLK1_HUMAN Inhibitor [2]
CDC-like kinase 2 (CLK2) TT85TPS CLK2_HUMAN Inhibitor [2]
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) TTSBVFO DYR1A_HUMAN Inhibitor [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5942).
2 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
3 Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
4 Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86.
5 Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61.
6 Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.